In 2019, Unimed has completed a series A financing of tens of millions of yuan, which was exclusively invested by CICC Capital. The financing proceeds will be used for the company's clinical testing center construction, completion of single cell capture system development, and promotion of assisted reproduction related projects. etc. Previously, our company completed a pre-A financing of 45 million yuan in 2017.

With the first marriage, to postpone the beginning of fertile age, as well as joint action "two child" policy, an increase in older mothers, the future which needs the help of artificial reproduction to the number of couples shows pregnant will increase significantly.

Founded in 2013, Unimed is a high-tech enterprise deeply involved in the field of reproduction and genetics. The company is mainly focused on pre-pregnancy genetic testing, preimplantation genetic testing (PGT), prenatal screening, prenatal diagnosis and so the whole industry chain service, successful resolution of fetal cells in maternal blood is difficult to efficiently capture and Century problem applied to commercial genetic testing.

Unimed has completed the entire industrial chain coverage in the field of reproductive genetics from genetic testing before embryo implantation to self-developed single-cell capture instrument for non-invasive prenatal diagnosis.

Breakthrough-Three Generations of IVF

Unimed is the first team in China to use SNP chips to provide genetic testing services for three generations of IVF preimplantation embryos. This team cooperated with the First Affiliated Hospital of Zhengzhou University in 2011 and successfully applied SNP chips to preimplantation Genetic diagnosis gave birth to China's first "chip baby."

The birth of "chip baby" proves that Unimed has the ability to provide qualified reproductive centers in China with the training of embryo biopsy to the implementation of all genetics before embryo implantation, including the construction of SNP chip platform, embryo biopsy, The training of PGT chip experiments, data analysis, interpretation of results, and delivery services for all reproductive genetic related projects, ultimately allow customers to fully master SNP chip technology and conduct PGT testing independently.

Innovation: cb-NIPT single-cell non-invasive prenatal gene detection technology

Unimed has original cb-NIPT single-cell non-invasive prenatal gene detection technology, which realizes non-invasive means to obtain free fetal cells in maternal blood, achieves whole-genome information detection at the single-cell level, and avoids the influence of maternal genetic information background. To determine the risk of fetal genetic disease.

The technical support Unipicker single-cell capture platform is the world's first fully automated rare cell capture platform, combined with specific marker staining was able to sample a variety of rare cells complete one billionth lossless capture, to meet a wide range of high and low downstream Sample requirements for throughput genetic testing, which can reduce the probability of false positives and false negatives caused by indirect detection.

Cb-NIPT results of clinical trials indicated that sensitivity to free prenatal testing cells reached 95% -99%, the detection sensitivity of single gene disorders also up to 90%. cb-NIPT enables identification of single cell-derived, fetus obtained complete genetic information, future scenarios is not only confined to prenatal diagnosis.

And Unimed is actively applying biological cell capture platform Class II Medical Device Registration Certificate, is expected to get the approval document by the end of 2020, to become a diagnostic product to prepare.

Fen Yi capital and Zhong Jin capital have expressed optimistic attitude about the prospects for the development of biological and Unimed would mobilize quality resources and financial support to Unimed, making it the leader in the field of reproductive genetic platform-level enterprise for our people to provide more accurate, more efficient, more comprehensive screening and diagnostic services.